Human Longevity (HLI), a US-based genomics research company backed by genomics firm Illumina, pharmaceutical company Celgene and industrial product manufacturer General Electric, yesterday obtained $30m in funding.
Emerging Technology Partners, identified as an existing shareholder, backed the round, as did several new, unnamed investors.
HLI was formed in 2014 to develop artificial intelligence-powered precision health analytics using technologies such as whole genome sequencing and brain and body imaging.
The platform, Health Nucleus, helps determine an individual’s risk of suffering from cardiac, metabolic and cognitive issues, as well as cancer. The latest funding will drive the further development of Health Nucleus.
HLI obtained an initial $70m in series A funding from Illumina and unnamed investors at launch, before adding a $10m extension later that same year thanks to unspecified backers.
Illumina, Celgene and General Electric subsequently backed a $220m series B round in 2016, the latter investing through its corporate venturing subsidiary, GE Ventures. The round also included undisclosed investors from the series A round.
